Bfsg LLC Purchases 3,490 Shares of OraSure Technologies, Inc. $OSUR

Bfsg LLC boosted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 8.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,680 shares of the medical instruments supplier’s stock after acquiring an additional 3,490 shares during the quarter. Bfsg LLC’s holdings in OraSure Technologies were worth $137,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC bought a new stake in OraSure Technologies during the second quarter worth $26,000. Strs Ohio bought a new stake in OraSure Technologies during the first quarter worth $481,000. Empowered Funds LLC raised its position in OraSure Technologies by 7.2% during the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock worth $1,366,000 after acquiring an additional 27,310 shares in the last quarter. NewEdge Advisors LLC raised its position in OraSure Technologies by 32,595.9% during the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock worth $161,000 after acquiring an additional 47,590 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of OraSure Technologies by 39.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,290,554 shares of the medical instruments supplier’s stock valued at $4,349,000 after purchasing an additional 363,946 shares during the period. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Price Performance

Shares of OSUR opened at $3.28 on Wednesday. The firm has a market capitalization of $239.90 million, a PE ratio of -4.90 and a beta of 0.44. The company’s 50-day moving average is $3.15 and its 200-day moving average is $3.06. OraSure Technologies, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $4.60.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.